Physicians’ favorable opinion of Remicade’s efficacy for treating moderate to severe Crohn’s disease and the drug’s higher price compared with Crohn’s disease therapies for which generic versions are available, such as prednisone and azathioprine, contribute to Remicade’s status as the current sales leader in this market. Decision Resources’ analysis of the Crohn’s disease drug market reveals that surveyed physicians who regard Remicade as the most efficacious therapy were most satisfied with the drug’s efficacy in induction of remission and response and its impact on quality of life. However, they were least satisfied with Remicade’s effect on maintenance of remission, corticosteroid-free remission, and response, presumably because of patients’ tendency to lose response to the drug over time. In contrast to surveyed gastroenterologists, the majority (60 percent) of surveyed managed care organizations’ (MCOs) pharmacy directors selected Abbott/Eisai’s Humira (adalimumab) as the most efficacious therapy for Crohn’s disease. Surveyed payers who selected Humira as the most efficacious therapy were most satisfied with the drug’s induction and maintenance of remission and response. The findings also reveal that surveyed gastroenterologists who selected Humira as most efficacious were most satisfied with its ability to improve patients’ quality of life. “Although only 23 percent of surveyed gastroenterologists chose Humira as the most efficacious therapy for Crohn’s disease, these physicians expressed a high level of satisfaction with Humira’s impact on quality of life and its effect on maintenance of remission, which will likely contribute to Humira’s increased use in the maintenance setting,” said Decision Resources Analyst MaryEllen Klusacek, Ph.D. “Considering all assessed efficacy end points, surveyed gastroenterologists were least satisfied with Humira’s effect on mucosal healing and fistula closure.” The findings also reveal that the Crohn’s disease drug market will experience modest growth over the next decade, increasing from approximately $3.2 billion in 2009 to $4.2 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. This moderate growth rate will mask dramatic changes as market growth from newer and emerging biological agents outpaces the decline in sales of older, established agents, which will face increasing generics competition and declining use. Tumor necrosis factor-alpha (TNF-alpha) inhibitors, namely Remicade and Humira, dominated the market in 2009, capturing nearly 77 percent of major-market sales. Additionally, several therapies with novel mechanisms of action are expected to launch for Crohn’s disease beginning in 2013, including Millennium Pharmaceuticals’ vedolizumab, Centocor Ortho Biotech/Janssen-Cilag’s Stelara (ustekinumab) and GlaxoSmithKline/ChemoCentryx’s GSK-1605786 (formerly CCX-282B or Traficet-EN).
CORPAK Acquires Merck Serono’s UK Gastroenterology Sales and Distribution Operation
Finance Thu, Sep 12, 2013, 9:35 PM EDT – U.S. Markets closed CORPAK Acquires Merck Serono’s UK Gastroenterology Sales and Distribution Operation Press Release: Mergers and Acquisitions Tue, Oct 2, 2012 8:00 AM EDT Print Related Content BUFFALO GROVE, IL–(Marketwire – Oct 2, 2012) – CORPAK MedSystems, Inc., a leading developer, manufacturer, and marketer of medical devices for the enteral-feeding and bedside-location markets, today announced it will acquire the gastroenterology sales and distribution operation of Merck Serono Limited in the UK and Ireland. Merck Serono had previously served as CORPAK’s distribution partner for the region. “The acquisition of the Merck Serono gastroenterology business strengthens our presence in Europe and our direct operation will support high levels of customer service and continued growth,” says Tom Kuhn, President of CORPAK. “I would like to thank the employees at Merck Serono for their support in building the CORPAK business in the UK and Republic of Ireland.” “The gastroenterology business is a strong and growing operation in the UK and Ireland, but Merck Serono has made a strategic decision to focus on our core pharmaceutical business,” explains Charles Dring, Commercial Director of Merck Serono Limited. “We have been working very closely with CORPAK to make the transition as seamless as possible for our customers.” There will be no change to the product range and all CORPAK products will continue to be available on the current codes and prices. The acquisition keeps relationships with existing sub-distributors unchanged. “We are especially pleased to be able to welcome the gastroenterology employees from Merck Serono to the CORPAK family,” says Jeff Blair, CEO of CORPAK. “We are confident that the UK and Ireland team will continue the history of excellence and dedication that has benefitted our customers in the past.” “This acquisition represents an important step in expanding our international presence and we look forward to continuing to provide our innovative, quality products to the European market,” added Eric Larson, Chairman of the CORPAK Board. CORPAK MedSystems UK ( http://www.corpakmedsystemsuk.com )